Reference is made to the stock exchange announcement on 25 September 2025 regarding the private placement under the financing facility with Long State Investments Limited.
For clarity, the reference to a “placement commission on market terms” relates to the standard transaction cost that applies when raising capital through such facilities/underwriters. This type of commission is customary in the capital markets and comparable to underwriting fees in larger placements. It does not represent a special benefit to Long State but reflects the normal compensation all underwriters receive when facilitating capital raises.
For further information, please contact:
Ulrik Spork, COB Soft Solutions AS, +45 31 38 83 87
Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165
Mail: ir@soft-ox.com
About SoftOx Solutions AS:
SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo. The company is developing highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The technology is based on extensive research and development in partnership with leading Nordic research institutes.